Insights

Strategic licensing ERS Genomics holds foundational CRISPR-Cas9 IP with multi-field use licenses and recent expansions such as the Early Access Express License, presenting opportunities to offer streamlined, early-stage access deals to pre-seed and pre-revenue biotech startups and research groups seeking rapid genome editing capabilities.

Partner expansion Recent licensing partnerships with Ricoh Group companies and Aurigene Pharmaceutical Services indicate ongoing interest from large corporates and service providers in integrating ERS Genomics’ CRISPR IP, suggesting a channel-focused sales approach targeting industrial MNCs and contract research providers.

Geographic reach Launch activity in Ireland, the UK and partnerships spanning the US and Japan point to a global market footprint; pursue regional licensing deals and localized support to maximize adoption in key biotech hubs and regulatory landscapes.

Commercial momentum Revenue tier positioned at modest levels with notable licensing activity and strategic announcements, signaling affordability and value for licensees; engage smaller biotechs and startups seeking cost-effective access while positioning ERS Genomics as a foundational tech partner.

Decision enablers Founders and leadership leadership changes (CEO appointment in 2024) combined with a strong patent portfolio and visible PLM for CRISPR IP can be leveraged to accelerate negotiations with potential licensees, R&D partners, and institutional buyers seeking credibility and long-term collaboration.

Similar companies to ERS Genomics

ERS Genomics Tech Stack

ERS Genomics uses 8 technology products and services including LinkedIn Ads, iCIMS, WordPress, and more. Explore ERS Genomics's tech stack below.

Media & News

ERS Genomics's Email Address Formats

ERS Genomics uses at least 2 email formats:
ERS Genomics Email FormatsExamplePercentage
First.Last@ersgenomics.comJohn.Doe@ersgenomics.com
80%
First.Middle@ersgenomics.comJohn.Michael@ersgenomics.com
20%

Frequently Asked Questions

What is ERS Genomics's official website and social media links?

Minus sign iconPlus sign icon
ERS Genomics's official website is ersgenomics.com and has social profiles on LinkedIn.

How much revenue does ERS Genomics generate?

Minus sign iconPlus sign icon
As of October 2026, ERS Genomics's annual revenue is estimated to be $1M - $10M.

What is ERS Genomics's SIC code and NAICS code?

Minus sign iconPlus sign icon
ERS Genomics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ERS Genomics have currently?

Minus sign iconPlus sign icon
As of October 2026, ERS Genomics has approximately 11 employees across 2 continents, including Europe and North America. Key team members include Chief Executive Officer: J. E. M., Vp Of Finance: R. K. F. and Head Of Commercial Operations: C. M. Explore ERS Genomics's employee directory with LeadIQ.

What industry does ERS Genomics belong to?

Minus sign iconPlus sign icon
ERS Genomics operates in the Biotechnology Research industry.

What technology does ERS Genomics use?

Minus sign iconPlus sign icon
ERS Genomics's tech stack includes LinkedIn Ads, iCIMS, WordPress, Salesforce, Shopify, Microsoft 365, OpenAI and Piwik PRO Core.

What is ERS Genomics's email format?

Minus sign iconPlus sign icon
ERS Genomics's email format typically follows the pattern of First.Last@ersgenomics.com. Find more ERS Genomics email formats with LeadIQ.

When was ERS Genomics founded?

Minus sign iconPlus sign icon
ERS Genomics was founded in 2014.
ERS Genomics logo

ERS Genomics

Biotechnology ResearchCalifornia, United States11-50 Employees

ERS Genomics, based in San Francisco, licenses the foundational CRISPR-Cas9 intellectual property developed by Emmanuelle Charpentier, providing access to researchers and companies across multiple fields of use. The organization draws on decades of genome editing and licensing experience to support development in therapeutics and related delivery technologies, spanning preclinical and clinical-stage programs.

A notable development in 2026 is the launch of the Early Access Express License, aimed at helping early-stage innovators access the CRISPR/Cas9 portfolio at the earliest stages of development. The company has also pursued partnerships to broaden access to its patent portfolio, including an integration with Aurigene Pharmaceutical Services Limited announced in May 2026.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
11-50

Section iconFunding & Financials

  • $1M - $10M

    ERS Genomics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.